Navigation Links
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
Date:4/10/2008

lop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection. Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources.

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. For more information please visit http://www.napopharma.com.

About Glenmark Pharmaceuticals Limited

Glenmark is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.] and metabolic disorders [Diabetes, Obesity, etc.]. The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark's speciality business alone is guided to generate $306 million (US) in Net Sales in fiscal year 2008 and $352 million (US) in fiscal year 2009. Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing Phase II clinical trials in the US. GRC 6211, undergoing Phase 2 clinical trials in Europe, has been outlicensed to Eli Lilly & company. Visit http://www.glenmarkpharma.com for further details.

About Crofelemer

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Crofelemer is in various stages of clinical d
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. Medarex Announces Ipilimumab Program Continues to Move Forward
11. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... 2007 - Geron,Corporation (Nasdaq:GERN) today announced the ... company's human,embryonic stem cell (hESC)-based therapeutic for ... direct attack by the human immune,system., Presented ... Federation of,Clinical Immunology Societies meeting in San ...
... BETHESDA, Md., June 11, 2007--New research supported ... of Arthritis and,Musculoskeletal and Skin Diseases (NIAMS) ... which is used for certain,types of seizures, ... pain and,other symptoms associated with the common, ...
Cached Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey has ... They’ve treated over 40,000 patients while carrying out their ... to the Paramus area. , For 2015, the practice ... of top-notch board certified physicians: Christine Milosis MD, Sandra Ugras ... doctors will work tirelessly to carry out The Doctor’s ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... researchers have identified an unexpected molecular marker that ... to chemotherapy. Triple-negative breast cancers --which do ... progesterone receptor and do not have Her2/neu overexpression ... of the disease and cannot be treated with ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... early stage prostate cancer, those who have the prostate gland ... a "watchful waiting" approach, according to a new long-term study ... to be practice-changing, said Dr. Richard E. Greenberg, chief of ...
... Gardner HealthDay Reporter , WEDNESDAY, May 4 ... was able to rectify ventricular fibrillation, a severely abnormal ... none experienced sudden death, according to new research. ... is already approved in Europe and is undergoing review ...
... May issue of the journal Health Affairs , Mount ... of toxic chemicals and air pollutants in the environment, and ... also those already on the market. Leonardo Trasande, ... Sinai School of Medicine, analyzed the costs of conditions ...
... MOINES, Iowa, May 4, 2011 The Donald Danforth Plant ... from the Howard G. Buffett Foundation to bring healthier sorghum ... help fund the completion of the development of biofortified sorghum, ... upon sorghum as their staple diet. DuPont business Pioneer ...
... Translational Genomics Research Institute (TGen) has licensed its first ... modifying the actions of proteins. Today,s announcement is ... laboratory discoveries more rapidly into therapeutics that can immediately ... drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings ...
Cached Medicine News:Health News:Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 3Health News:New Defibrillator Shows Promise in Small Study 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 3Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:TGen licenses first drug for patient use in clinical care 2
Inquire...
... incubators,Two refrigerated incubators that are ... life cycle,testing. Microprocessor controlled heating ... display. High/low audible and visual ... internal chamber safety thermostat,provides over-temperature ...
Inquire...
Inquire...
Medicine Products: